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Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in
diabetic nephropathy.
Background. We have already reported Gas6 is involved
in glomerular hypertrophy observed in diabetic nephropathy.
However, the molecular mechanisms involved in glomerular
hypertrophy are still unknown, especially in vivo.
Methods. In vivo, diabetes was induced in rats and mice by
streptozotocin (STZ) and the activation of the Akt/mTOR path-
way in glomeruli was examined. In vitro, mesangial hypertrophy
was assessed by [3H]leucine incorporation and measuring cell
areas.
Results. Akt, p70 S6 kinase, and 4E-BP-1 were induced and
phosphorylated in rat glomerular lysates after 12 weeks of STZ
injection when mesangial and glomerular hypertrophy was ob-
served. We then examined the role of Gas6 by treating STZ-
rats with warfarin, and found that warfarin treatment inhibited
the phosphorylation of these molecules as well as the hyper-
trophy. We next examined whether high glucose stimulation
can induce the expression of Gas6/Axl in mesangial cells. Stim-
ulation of the cells with 25 mmol/L of glucose increased the
expression of Gas6/Axl and mesangial cell size compared with
that with 5.6 mmol/L of glucose. This hypertrophic effect was
abolished in mesangial cells derived from Gas6 knockout mice.
We also found that LY294002 and rapamycin blocked Gas6-
induced activation of the Akt/mTOR pathway and mesangial
hypertrophy. Furthermore, less phosphorylated Akt-positive or
4E-BP-1–positive areas were found in STZ-treated Gas6 knock-
out mice than in STZ-treated wild-type mice.
Conclusion. Our study indicates that the Akt/mTOR path-
way is a key signaling cascade in Gas6-mediated mesangial and
glomerular hypertrophy and revealed a crucial role of Gas6/Axl
and the Akt/mTOR pathway in the development of diabetic
nephropathy.
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Renal disease is a common, but poorly understood,
complication of diabetes. Diabetic nephropathy is the
most common cause of end-stage renal disease in many
countries, affecting approximately 30% of type 1 diabetic
patients [1, 2], and begins with mesangial and glomerular
hypertrophy, followed by accumulation of extracellular
matrix components secreted mainly from mesangial cells.
Mesangial cells, thus, play a key role in the glomerular
hypertrophy of early diabetic nephropathy [3]. Following
the initial step of nephropathy characterized by glomeru-
lar hypertrophy, glomerulosclerosis develops, leading to
progressive loss of renal function [4]. Because it is im-
portant to regulate the early stage of the disease process,
extensive efforts have been made to elucidate growth fac-
tors and cytokines involved in mesangial expansion and
hypertrophy [5]. Transforming growth factor-b1 (TGF-
b1) [6, 7], insulin-like growth factor-1 (IGF-1) [8], an-
giotensin II (Ang II) [9, 10], and others have been
implicated in diabetic nephropathy. However, only block-
ing Ang II-aldosterone-mediated renal damage is cur-
rently used in clinical settings for the treatment of
diabetic nephropathy [11].
We have reported that growth arrest–specific gene 6
(Gas6) and its receptor, Axl, play a key role in the devel-
opment of glomerular hypertrophy in the initial phase
of diabetic nephropathy by inducing mesangial hyper-
trophy in vivo and in vitro [12]. Gas6 is a new growth
factor for mesangial cells, post-translationally activated
by c-carboxylation in the presence of vitamin K, and in-
activated by warfarin. Warfarin is an inhibitor of Gas6,
currently used to prevent blood coagulation [13, 14]. In
our previous study, we showed that Gas6 and Axl were
induced in glomeruli in STZ-induced diabetic rats as
glomerular hypertrophy progressed. We also found that
Gas6 caused mesangial hypertrophy, and that adminis-
tration of warfarin inhibited the hypertrophy as well as
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hyperfiltration and albuminuria in diabetic rats. Further,
by inducing diabetes with STZ in Gas6 knockout mice,
we confirmed that Gas6 is involved in the development
of mesangial and glomerular hypertrophy. However, the
signaling molecules involved in the mesangial hypertro-
phy, and how Gas6 is regulated in diabetic nephropathy,
remain unknown.
Several lines of evidence implicate the Akt/mTOR
pathway responsible for mesangial hypertrophy. Fingar
et al reported that mammalian cell size is regulated by
Akt and its downstream, p70 S6 kinase and 4E-BP-1
[15]. Gorin et al showed that Ang II induces protein syn-
thesis in mesangial cells via Akt activation [16]. IGF-1
has been shown to induce cellular hypertrophy through
the Akt/mTOR pathway in skeletal myotube [17]. IGF-1
can also induce mesangial hypertrophy via a calcineurin-
dependent mechanism [18]. Endothelin-1, on the other
hand, can induce mesangial hypertrophy via activa-
tion of p44/42 mitogen-activated protein (MAP) kinase,
c-Jun N-terminal protein kinase, and PI3-kinase path-
ways [19]. Thus, Akt would be one of the molecules im-
portant for the mesangial hypertrophy characteristic of
diabetic nephropathy. However, these studies analyzing
the signaling cascade in mesangial hypertrophy were per-
formed only in vitro, and no report has studied the sig-
naling mechanism involved in mesangial hypertrophy in
vivo as well as in vitro.
p27 is a cyclin-dependent kinase inhibitor and could
be a key protein for mesangial hypertrophy [20]. High
glucose stimulation increases expression of p27 and
mesangial cell size, which is inhibited by p27 antisense
oligonucleotides in vitro [21]. In diabetic db/db mice,
p27-positive glomerular cells increased in size signifi-
cantly, and its expression was mainly restricted to nuclei
of mesangial cells [22]. TGF-b1–mediated mesangial hy-
pertrophy was also shown to be reduced in the absence
of p27 [23]. These data suggest that p27 is one of the im-
portant markers that regulate G1-phase cell cycle arrest
and cellular hypertrophy. Therefore, the relationship be-
tween Akt and p27 should be also clarified in diabetic
nephropathy.
The present study, therefore, examines whether the
Akt/mTOR pathway is involved in mesangial cell hy-
pertrophy, a major mechanism responsible for glomeru-
lar hypertrophy in vivo and in vitro. In vivo, we used
STZ-rats and examined the activation of Akt and its
downstream signaling molecules, p70 S6 kinase and 4E-
BP-1, and expression of p27 in glomeruli. Further, we an-
alyzed the activation of Akt and 4E-BP-1 in STZ-treated
Gas6 knockout mice glomeruli. In vitro, by using pri-
mary culture mesangial cells, the effect of high glucose on
Gas6/Axl, the role of Gas6/Axl in high glucose-induced
mesangial hypertrophy, and the role of Akt/mTOR
pathway in Gas6-induced mesangial hypertrophy were
examined.
METHODS
Antibodies and reagents
STZ was obtained from Wako Pure Chemical, Inc.,
Ltd. (Osaka, Japan). Rabbit anti-Akt, anti-phospho-Akt,
anti-p70 S6 kinase, anti-phospho-p70 S6 kinase, anti-4E-
BP-1, anti-phospho-4E-BP-1, anti-phospho-p44/42 MAP
kinase polyclonal antibody were from Cell Signaling
Technology (Beverly, MA, USA). Goat anti-Axl and rab-
bit anti-p27 antibody were from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). Cell culture dishes were
from Nalge Nunc International (Roskilde, Denmark).
Dulbecco’s modified Eagle’s medium (DMEM) and fe-
tal calf serum were from Invitrogen (Carlsbad, CA,
USA). Bovine serum albumin (BSA) and U0126 were
from Sigma-Aldrich (St. Louis, MO, USA). Axl-Fc,
recombinant rat Gas6, and Gla-defective Gas6 were pre-
pared as described previously [12–14]. Human Fc por-
tion was from ICN Biomedicals, Inc. (Irvine, CA, USA).
LY294002 was from Calbiochem (La Jolla, CA, USA).
Rapamycin was from Nacalai Tesque, Inc. (Kyoto, Japan).
Animals and cell culture
Male Sprague-Dawley rats were purchased from
Shimizu Laboratory Animal Center (Hamamatsu,
Japan). Gas6 knockout mice were generated with a tar-
geted disruption of the Gas6 gene, and generation of
these mice has been described previously [24]. Their
background was C57BL/6, and control inbred C57BL/6
mice were obtained from Clea Japan, Inc. (Osaka, Japan).
Animals were housed under specific pathogen-free con-
ditions at the Animal Facilities of Kyoto University, Fac-
ulty of Medicine. All animal experiments were performed
in accordance with institutional guidelines, and the Re-
view Board of Kyoto University granted an ethical per-
mission to this study. Mouse kidney mesangial cells were
characterized and maintained as previously described
[25, 26].
STZ-induced diabetic rats and mice
Male rats weighing 170 to 200 g and female weight-
matched 8-week-old mice (17–20 g) were made diabetic
as described previously [12]. Twelve weeks after injection
of STZ, rats and mice were killed for analysis.
Warfarin treatment
Rats were divided into 4 groups (N = 6 in the control
group and N = 10 in the diabetic group); control rats
without treatment, control rats with warfarin treatment,
diabetic rats without treatment, and diabetic rats with
warfarin treatment. The warfarin treatment was done as
described previously [12]. Warfarin potassium was pro-
vided by Eisai Co., Ltd. (Tokyo, Japan).
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Histologic studies
Upper pole of kidney from each animal was fixed in
methyl Carnoy’s solution and embedded in paraffin. Sec-
tions (2 lm) were stained with periodic acid–Schiff. The
remaining kidney tissues were snap frozen in cold ace-
tone in OCT compound (Sakura Finetechnical Co., Ltd.,
Tokyo, Japan), and cryostat sections (4 lm) were stained
by indirect immunohistochemistry procedure with the
following primary antibodies: rabbit polyclonal antibody
against rat Gas6 [27], phospho-Akt, and phospho-4E-BP-
1 (Cell Signaling Technology), respectively. For rats, sec-
tions were incubated with Histofine Simple Stain MAX-
PO (Nichirei Co., Tokyo, Japan) for 30 minutes and then
incubated with DAB solution (Vector, Burlingame, CA,
USA). Finally, nuclei were stained by Methyl Green
(Dako, Carpinteria, CA, USA). For mice, sections were
incubated with FITC-conjugated donkey antirabbit IgG
antibody (Chemicon International, Inc., Temecula, CA,
USA) for phopho-Akt, and with TSATM Biotin System
(PerkinElmer Life Sciences, Boston, MA, USA) accord-
ing to manufacturer’s instructions for phospho-4E-BP-
1. The stained areas of 30 glomeruli were measured by
Image-Pro Plus (Media Cybernetics, Silver Spring, MD,
USA).
Isolation of glomeruli
Rat glomeruli were isolated from renal cortex of rats
using the differential sieving method [28, 29]. The purity
of the glomeruli was >90%.
Measurement of mesangial cell size
Mesangial cells derived from wild type or Gas6 knock-
out mice were incubated in DMEM with either low
(5.6 mmol/L) or high (25 mmol/L) glucose containing
0.5% BSA, whose osmolarity had been adjusted by
sodium pyruvate (1 mmol/L). After 36 hours, cells were
fixed with acetone for 10 minutes and stained with rho-
damine phalloidin (Molecular Probes, Inc., Eugene, OR,
USA) to visualize their outlines. The areas of 500 cells
were measured by Image-Pro Plus (Media Cybernetics).
[3H]leucine incorporation and determination of cell
number
For determination of [3H]leucine incorporation,
mesangial cells were precipitated with 10% trichloro-
acetic acid (Wako Pure Chemical Inc., Ltd.), and counted
in a liquid scintillation counter (Beckman Coulter, Fuller-
ton, CA, USA). For determination of cell number,
the cells were trypsinized, resuspended in phosphate-
buffered saline, and counted with a Coulter counter Z1
(Coulter Electronics, Ltd., Hialeah, FL, USA). The data
were normalized by dividing incorporation counts by the
cell number.
Ribonuclease protection assay
Total RNA was extracted using TRIzol reagent
(Invitrogen), and analyzed by ribonuclease protection
assay. First, we constructed a mouse Gas6 probe. A
fragment of mouse Gas6 cDNA (234 bp) was obtained
by polymerase chain reaction (PCR) using the primer
pair 5′-GCTTTCTAGATCTCTTCGGTACAATGGC-
3′ and 5′-CGGCTGGACGAGCTCACTCTC-3′. The
PCR fragment was confirmed to be the mouse gas6 cDNA
by DNA sequencing and was cloned into pBluescript
II KS (+). After digesting the plasmid with Bgl II, an
antisense riboprobe was synthesized in vitro using T7
RNA polymerase. Ribonuclease protection assays were
then performed according to the manufacturer’s proto-
col (RPA IIITM; Ambion, Inc., Austin, TX, USA). The
protected bands were evaluated by densitometric anal-
ysis using GS-800 Calibrated Densitometer and Quan-
tity One (Bio-Rad Laboratories, Hercules, CA, USA)
[30].
Quantitative PCR
Quantitative PCR was performed using real time
Taqman TM technology according to the manufacturer’s
protocol, and analyzed on a Model 7900 sequence
detector (Applied Biosystems, Foster City, CA, USA)
[31]. Forward and reverse primers and the Taqman probe
for Gas6 are 5′-AGGCTCAACTACACCCGAACAT-
3′, 5′-GGATCCGAGCCACAACTTTAAC-3′, and
5′-CTGGATGTCGGCACGGAAACCAC -3′, respec-
tively. Primers and the Taqman probe for 18s ribosomal
RNA were purchased from Applied Biosystems.
Western blotting
Isolated glomeruli or harvested mesangial cells were
suspended in RIPA buffer [12], and rotated for 1 hour
at 4◦C. After centrifugation of the samples, the super-
natants were used as total cell lysates. Then, each sample
was applied to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and immunoblotted.
Immunoprecipitation
High glucose-stimulated mesangial cell lysates were
homogenized with Cell Lysis BufferTM (Cell Signaling
Technology), and subjected to immunoprecipitation for 2
hours at 4◦C with anti-p70 S6 kinase antibody. Antibody-
antigen complexes were collected by incubation for 45
minutes with Protein A-agarose (Roche Diagnostics Cor-
poration, Indianapolis, IN, USA) at 4◦C. After the beads
were washed twice with Cell Lysis BufferTM, bound pro-
teins were denatured in SDS sample buffer. The samples
were separated on SDS-PAGE and immunoblotted.
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Fig. 1. Activation of the Akt/mTOR pathway in diabetic rat glomeruli.
(A) The serial profile of body weight and blood sugar values in STZ-
rats. (B to E) After 12 weeks of STZ injection, the upper pole of kidney
was fixed in methyl Carnoy’s solution and embedded in paraffin. Sec-
tions (2 lm) were stained with periodic acid–Schiff. A representative
glomerulus from each group of rats (B, control rats without treatment; C,
control rats with warfarin treatment; D, diabetic rats without treatment;
E, diabetic rats with warfarin treatment) was exemplified. The original
magnification was ×400. (F) After 12 weeks of STZ injection, isolated
glomeruli were suspended in RIPA buffer. Sixty lg of each sample was
analyzed by Western blotting with the antibodies indicated. The bands
immunoblotted with anti-p70 S6 kinase and anti-4E-BP-1 antibody in-
creased in size when phosphorylated (arrows). Each lane represents a
representative Western blot from each rat. Abbreviations are: Wa, war-
farin treatment; pAkt, phospho-Akt; pp70 S6 kinase, phospho-p70 S6
kinase; p4E-BP-1, phospho-4E-BP-1.
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Fig. 2. Expression and localization of phosphorylated Akt and Gas6
in STZ-rat glomeruli. Kidney tissues from each animal as in Figure 1
were snap frozen in cold acetone in OCT compound. Cryostat sections
(4 lm) were stained using indirect immunohistochemistry procedure
with anti-phospho-Akt (A, B) or anti-Gas6 (C, D) antibody. (A) and
(C) were from control and (B) and (D) were from STZ-rats. The original
magnification was ×400. Abbreviations are: pAkt, phospho-Akt.
WT control (B,G)
WT Diabetes (D,I)
KO control (C,H)
KO Diabetes (E,J)
25
20
15
Bo
dy
 w
ei
gh
t, 
g
0 4 8 12
(week)
0 4 8 12
(week)
30
25
20
15
10
5
0B
lo
od
 s
ug
ar
,
 
m
m
o
l/L
X400
X400
400
300
200
100
0
p4
E-
BP
-1
 p
os
itiv
e 
ar
ea
pe
r g
lo
m
er
ul
ar
 c
ro
ss
 s
ec
tio
n,
 µ
m
2
* **
WT KO WT KO
ControlDiabetes
K
400
300
200
100
0
WT KO WT KO
pA
kt
 p
os
itiv
e 
ar
ea
pe
r g
lo
m
er
ul
ar
 c
ro
ss
 s
ec
tio
n,
 µ
m
2
* **
ControlDiabetes
F
A
556 Nagai et al: Gas6 and Akt/mTOR pathway in glomerular hypertrophy
Cell transfection and mesangial cell
immunohistochemistry
Mesangial cells (0.75 × 104/well) were plated in 8-
well Lab-TekTM chamber slides (Nalge Nunc Interna-
tional). Twelve hours later, the cells were transfected with
myc-tagged cDNAs expressing constitutive active, wild
type, or dominant negative Akt (Upstate, Charlottesville,
VA, USA) by using FuGene 6 Transfection Reagent
(Roche Diagnostics Corporation) according to the man-
ufacturer’s instructions, respectively. Twelve hours after
transfection, cells were serum-starved in DMEM con-
taining 0.5% BSA. After 36 hours, cells were fixed with
acetone for 10 minutes and immunostained with mouse
monoclonal anti-myc antibody (Santa Cruz Biotechnol-
ogy), followed by Alexa-labeled goat antimouse IgG
antibody (Molecular Probes, Inc.). The areas of 500
stained cells were measured by Image-Pro Plus (Media
Cybernetics).
Statistical analyses
The data are expressed as mean ± SD. Comparison
among each group was performed by one-way analysis
of variance (ANOVA) followed by Neuman-Keuls test
to evaluate statistical significance between two groups.
A P value of less than 0.05 was considered statistically
significant.
RESULTS
Phosphorylation of Akt, P70 S6 kinase, and 4E-BP-1, and
induction of p27 expression in diabetic rat glomeruli
To examine the role of Akt in Gas6-induced mesan-
gial hypertrophy in vivo, we divided rats into 4 groups;
control rats without treatment, control rats with warfarin
treatment, diabetic rats without treatment, and diabetic
rats with warfarin treatment. The body weight and blood
glucose level were almost the same in control and diabetic
rats with or without warfarin treatment during the study
period (Fig. 1A). After 12 weeks of STZ injection, sig-
nificant enlargement of glomeruli was observed (Fig. 1B
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 6. Effect of Gas6 deficiency on phosphorylated Akt and 4E-BP-1
expression in STZ-treated mice glomeruli. (A) The serial profile of body
weight and blood sugar values in STZ-mice. (B to E, G to J) After 12
weeks of STZ injection, the mice were killed and the kidney tissues from
each mouse were stained using indirect immunofluorescence procedure
with anti-phospho-Akt (B-E) or anti-phospho-4E-BP-1 (G-J) antibody.
A representative glomerulus from each group of mice (B, G: nontreated
wild-type mice; C, H: nontreated Gas6 knockout mice; D, I: STZ-treated
wild-type mice; E, J: STZ-treated Gas6 knockout mice) was exemplified.
The original magnification was ×400. (F and K) Immunostained area
was then measured as described in Methods. The data are expressed
as mean ± SD (N = 3 in the control group and N = 5 in the diabetic
group). ∗P < 0.01, ∗∗P < 0.05. Abbreviations are: pAkt, phospho-Akt;
p4E-BP-1, phospho-4E-BP-1; WT, wild type mice; KO, Gas6 knockout
mice.
to E). Warfarin treatment of the rats resulted in a sig-
nificant decrease in glomerular size as previously shown
[11]. We then examined the expression of Akt and its
downstream signaling molecules, p70 S6 kinase and 4E-
BP-1, in diabetic glomeruli, and found that Akt, p70 S6
kinase, and 4E-BP-1 were induced and phosphorylated
in rat glomerular lysates after 12 weeks of STZ injection
when mesangial and glomerular hypertrophy were ob-
served. Warfarin treatment of STZ-rats inhibited the in-
duction and phosphorylation of these molecules (Fig. 1F),
which is consistent with the effect of warfarin on the hy-
pertrophy, as previously described for glomerular filtra-
tion rate and urine albumin excretion [12]. These data
suggest that Gas6 is involved in glomerular hypertro-
phy via the Akt/mTOR pathway in vivo. We also ex-
amined the expression of p27, an inhibitor of G1 phase
cyclin-dependent kinase. Intriguingly, its induction com-
pletely paralleled the phosphorylation of Akt, p70 S6
kinase, and 4E-BP-1, indicating that the Akt/mTOR
pathway itself could play a role in glomerular hyper-
trophy in vivo. To examine whether Akt is activated in
mesangial cells, immunohistochemical analysis was per-
formed in STZ-rats. We found that phosphorylation of
Akt was increased mainly in mesangial cells (Fig. 2A and
B), and that its localization was almost the same with that
of Gas6 (Fig. 2C and D). These data suggest that Gas6 and
the Akt/mTOR pathway would be involved in glomeru-
lar hypertrophy via mesangial hypertrophy in the early
phase of diabetic nephropathy.
High glucose induces mesangial hypertrophy via Gas6/
Axl in vitro
To elucidate how Gas6/Axl is involved in the devel-
opment of diabetic nephropathy, we evaluated mesan-
gial cell size by [3H]leucine incorporation in vitro and
found that stimulation of the cells with high glucose in-
creased the incorporation by 1.15-fold (Fig. 3A and B).
This hypertrophic effect was inhibited by addition of Axl-
Fc, a specific inhibitor of the Gas6/Axl pathway (Fig. 3A)
[27], and abrogated in mesangial cells derived from Gas6
knockout mice (Fig. 3B). Further, we confirmed mesan-
gial cell hypertrophy in high glucose condition by mea-
suring cell areas under the same protocol as in Fig. 3B
(Fig. 3C), indicating that Gas6 plays a specific role in
high glucose-induced mesangial hypertrophy. To show
that both Gas6/Axl and the Akt/mTOR pathway are in-
volved in high glucose-induced mesangial hypertrophy,
we examined whether high glucose stimulation can in-
duce the expression of Gas6/Axl and the activation of
Akt/mTOR in mesangial cells in vitro. Stimulation of
the cells with high glucose for 3 hours resulted in an in-
creased expression of Gas6 by 1.3-fold at mRNA levels
compared with that with low glucose (Fig. 3D). This result
was confirmed by quantitative real-time PCR (1.32-fold
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Fig. 3. High glucose induces mesangial hy-
pertrophy through Gas6 induction. (A) Me-
sangial cells were plated at 1.5 × 104 cells/well
in 24-well dishes. After 48 hours, cells were
serum-starved in DMEM with either low
(5.6 mmol/L) or high (25 mmol/L) glucose
containing 0.5% BSA in the presence or ab-
sence of Axl-Fc (20 nmol/L). Human Fc por-
tion (20 nmol/L) was used as control. After
24 hours, cells were labeled with [3H]leucine
(2 lCi/mL) for 12 hours, and incorporation of
[3H]leucine and cell number were then deter-
mined as described in Methods. The data were
normalized by dividing incorporated counts
by the cell number and showed as fold in-
creases over control. The values expressed are
the mean ± SD of 4 independent experiments.
∗∗P < 0.05. (B) Mesangial cells derived from
wild-type or Gas6 knockout mice were stim-
ulated with low or high glucose, and incorpo-
ration of [3H]leucine and cell number were
measured as described above. The values ex-
pressed are the mean ± SD of 4 independent
experiments. ∗∗P < 0.05. (C) Mesangial cells
were treated as described in (B) and the cell
size was measured as described in Methods.
The values expressed are the mean ± SD of
500 cell areas. ∗P < 0.01. (D) Mesangial cells
were plated at 4.5 × 105 cells/dish in 10 cm
dishes. After 48 hours, the medium was re-
placed in DMEM with either low or high glu-
cose containing 10% fetal calf serum. Three
hours after the replacement, the cells were
harvested and total RNAs were extracted and
analyzed by ribonuclease protection assay as
described in Methods. The protected bands
for each RNA probe were evaluated by den-
sitometric analysis. The values expressed are
the mean ± SD of 3 independent experiments.
∗P < 0.01. (E) Mesangial cells were treated as
described in (B). After 36 hours, cells were
suspended in cell lysis buffer for the detec-
tion of p70 S6 kinase or RIPA buffer for
the others. After centrifugation of the sam-
ples, the supernatants were used as total cell
lysates. For the evaluation of p70 S6 kinase,
the cell lysates were immunoprecipitated with
anti-p70 S6 kinase antibody according to the
manufacturer’s instructions and immunoblot-
ted with anti-p70 S6 kinase or phospho-p70
S6 kinase antibody. For the evaluation of the
others, 20 lg of each sample was applied to
SDS-PAGE and immunoblotted with the an-
tibody indicated. Representative data were
shown from four independent experiments.
Abbreviations are: pAkt, phospho-Akt; pp70
S6 kinase, phospho-p70 S6 kinase; low, low
glucose; high, high glucose
increase over low glucose). Stimulation with high glucose
for 36 hours also significantly increased expression of Axl
and phosphorylated Akt and its downstream molecules
in mesangial cells derived from wild-type mice, but not in
those from knockout mice (Fig. 3E).
Gas6 activates Akt, P70 S6 kinase, and 4E-BP-1 in vitro
We previously showed that Gas6 and Axl are up-
regulated in the diabetic glomeruli and are involved in
mesangial and glomerular hypertrophy in vivo and in
vitro [12]. Because warfarin inhibited the hypertrophic
effect of Gas6/Axl and activation of the Akt/mTOR path-
way in vivo, we next examined whether Gas6 can acti-
vate the Akt/mTOR pathway in mesangial cells in vitro.
After stimulation of mesangial cells with the indicated
concentrations of Gas6 for 30 minutes, phosphorylation
of Akt, p70 S6 kinase, and 4E-BP-1 was examined by
Western blotting. As shown in Figure 4A, Gas6 increased
phosphorylation of Akt, p70 S6 kinase, and 4E-BP-1
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Fig. 4. Gas6-mediated phosphorylation of the Akt/mTOR pathway in
mesangial cells. (A) Mesangial cells were plated at 1.5 × 105 cells/dish in
6 cm dishes. After 48 hours, cells were serum-starved in DMEM contain-
ing 0.5% BSA for 48 hours. Medium was changed to serum-free DMEM,
and cells were incubated for another 2 hours. The cells were then stimu-
lated with the indicated concentrations of Gas6 for 30 minutes, and the
cell lysates (20 lg) were subjected to immunoblotting with the antibod-
ies indicated. (B) Mesangial cells were treated as described above. The
cells were stimulated with 100 ng/mL of Gas6 for the indicated times,
and the cell lysates (20 lg) were subjected to immunoblotting with the
antibodies indicated. (C) The cells were stimulated with vehicle or Gas6
(100 ng/mL) after preincubation with or without Axl-Fc (20 nmol/L) for
30 minutes. Human Fc protein (20 nmol/L) was used as negative con-
trol. The cell lysates (20 lg) were subjected to immunoblotting with
the antibodies indicated. Representative data were shown from 4 inde-
pendent experiments. Abbreviations are: pAkt, phospho-Akt; pp70 S6
kinase, phospho-p70 S6 kinase.
in a dose-dependent manner and reached a plateau at
100 ng/mL. The same dose of Gla-defective Gas6, which
is an inactive form of Gas6 without c-carboxylation, did
not affect phosphorylation of these molecules. In a time
course experiment, phosphorylation of these molecules
by 100 ng/mL of Gas6 increased in a time-dependent
manner and peaked at 15 to 30 minutes (Fig. 4B). The
peak of Akt phosphorylation was earlier than that of
p70 S6 kinase and 4E-BP-1 phosphorylation. Further, to
examine whether Gas6 can specifically induce the phos-
phorylation of these signaling molecules, we treated
mesangial cells with 100 ng/mL of Gas6 preincubated
with 20 nmol/L of Axl-Fc. Gas6-induced phosphorylation
was abolished by the preincubation with Axl-Fc, indicat-
ing that the phosphorylation was specifically induced by
Gas6 (Fig. 4C).
LY294002 and rapamycin block Gas6-induced mesangial
hypertrophy in vitro, while U0126 does not
We next examined whether LY294002, a PI3 kinase
inhibitor, and rapamycin, an mTOR inhibitor, which are
two representative inhibitors of the Akt/mTOR pathway,
can affect mesangial hypertrophy and phosphorylation of
the signaling molecules induced by Gas6. Mesangial cells
were preincubated with each inhibitor for 1 hour, and
were stimulated with 100 ng/mL of Gas6 for 24 hours
for [3H]leucine incorporation. As shown in Figure 5A,
both LY294002 and rapamycin inhibited Gas6-induced
mesangial hypertrophy, while U0126 did not. Under the
same pretreatment protocol, cells were stimulated with
100 ng/mL of Gas6 for 30 minutes for Western blotting.
Phosphorylation of Akt, p70 S6 kinase, and 4E-BP-1 was
blocked by LY294002, while phosphorylation of p70 S6
kinase and 4E-BP-1 was blocked by rapamycin (Fig. 5B).
Phosphorylation of p44/42 MAP kinase was not affected
by either inhibitor. U0126 blocked phosphorylation of
p44/42 MAP kinase, but did not affect the phosphoryla-
tion of Akt, p70 S6 kinase, or 4E-BP-1.
Activation of Akt can cause mesangial hypertrophy
To determine whether activation of Akt itself can in-
duce mesangial hypertrophy, we transfected mesangial
cells with myc-tagged cDNAs expressing constitutive
active, wild type, or dominant-negative mutants of Akt.
Twelve hours after transfection, cells were serum-starved
for 36 hours. We then fixed the cells and stained them
with anti-myc antibody. The size of cells expressing the
myc epitope was then determined. The mesangial cell size
transfected with constitutive active Akt was significantly
greater than that with wild-type Akt (2.64 × 103 ± 1.13 ×
103 vs. 2.39 × 103 ± 1.06 × 103 lm2, P < 0.05) or dominant-
negative Akt (2.31 × 103 ± 1.02 × 103 lm2, P < 0.01).
STZ-treated Gas6 knockout mice showed less activation
of Akt and 4E-BP-1 in glomeruli
We have shown the involvement of Gas6 in mesan-
gial and glomerular hypertrophy in STZ-rats, as well as
in STZ-mice by using Gas6 knockout mice [12]. To fur-
ther confirm the specificity of the Akt/mTOR pathway
in Gas6-mediated mesangial hypertrophy, we checked
the phosphorylation of Akt and 4E-BP-1 in STZ-mice
glomeruli. The body weight and blood glucose level were
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Fig. 5. LY294002 and rapamycin can block
Gas6-induced mesangial hypertrophy and
phosphorylation of the Akt/mTOR pathway,
but not U0126. (A) Mesangial cells were
serum-starved in DMEM containing 0.5%
BSA for 48 hours. After preincubation with
20 lmol/L of LY294002, 20 ng/mL of ra-
pamycin or 10 lmol/L of U0126 for 1 hour,
the cells were stimulated with 100 ng/mL of
Gas6. After 18 hours, the cells were labeled
with [3H]leucine (2 lCi/mL) for 6 hours. In-
corporation of [3H]leucine and cell number
were then determined as described in Meth-
ods. The data were normalized by dividing
incorporated counts by the cell number and
showed as fold increases over control. The
values expressed are the mean ± SD of 4 inde-
pendent experiments. ∗P < 0.01. (B) Mesan-
gial cells were treated as described above.
The cells were stimulated with 100 ng/mL of
Gas6 for the indicated times, and their lysates
(20 lg) were subjected to immunoblotting
with the antibodies indicated. Representative
data were shown from 4 independent exper-
iments. Abbreviations are: pAkt, phospho-
Akt; pp70 S6 kinase, phospho-p70 S6 kinase;
pp44/42 MAP kinase, phospho-p44/42 MAP
kinase.
almost the same in diabetic wild-type and knockout
mice (Fig. 6A). After 12 weeks of STZ injection, we
stained the kidney section with anti-phospho Akt or
anti-phospho-4E-BP-1 antibody and measured the pos-
itive area. STZ-treated wild-type mice showed larger
phosphorylated Akt or 4E-BP-1-positive areas than non-
treated wild-type mice, while STZ-treated Gas6 knock-
out mice showed significantly less phosphorylated Akt
or 4E-BP-1–positive areas than STZ-treated wild-type
mice, suggesting that Gas6-induced mesangial hypertro-
phy is specifically through the Akt/mTOR pathway in
vivo (Fig. 6B to K).
DISCUSSION
In this study, we have shown that Akt, p70 S6 kinase,
and 4E-BP-1 are key signaling molecules in the mesan-
gial hypertrophy characteristic of the early stage of di-
abetic nephropathy in vivo and in vitro. This is the first
demonstration that the Akt/mTOR pathway is activated
mainly in mesangial cells when mesangial and glomeru-
lar hypertrophy is observed in the early stage of diabetic
nephropathy in vivo, and that Gas6 may be one of the
molecules involved in the activation of this pathway. Our
study implies that Gas6 can play a crucial role in the de-
velopment of the initial phase of diabetic nephropathy
by activating signaling molecules critical for determin-
ing the cell size. Presumably, activation of these signaling
molecules can lead to functional changes characteristic
of diabetic nephropathy and deposition of extracellular
matrix in the glomeruli.
Previous studies have shown that Akt regulates pro-
liferation [32, 33] and survival [34] of mesangial cells in
vitro. Others have shown the importance of Akt in Ang
II- and endothelin-1–induced mesangial hypertrophy [16,
19, 35] in vitro. In vivo, Feliers et al have demonstrated
that the Akt/mTOR pathway is activated in renal cor-
tex in diabetic db/db mice [36], a model of type II dia-
betic nephropathy. However, the role of the Akt/mTOR
pathway especially in mesangial hypertrophy in diabetic
renal disease was not investigated in vivo, and no study
has linked the in vitro and in vivo data. In this study,
therefore, we have provided compelling evidence by
showing the activation of the Akt/mTOR pathway, in-
duction of p27, and localization of phosphorylated Akt in
mesangial cells of diabetic glomeruli in vivo. In addition,
STZ-treated Gas6 knockout mice showed less phospho-
rylated Akt-positive areas than STZ-treated wild-type
mice. Further, we could connect these in vivo data to
in vitro data by showing that Gas6 can be induced by
high glucose and can induce mesangial hypertrophy in an
Akt-dependent manner.
We showed that the Akt/mTOR pathway is a key sig-
naling cascade in mesangial and glomerular hypertrophy
in vivo and in vitro. However, there is some discrepancy
between the results in vitro and in vivo. Cultured mesan-
gial cells, for example, express Akt even in an unstimu-
lated condition, while Akt was hardly detectable in con-
trol glomeruli in vivo. This difference might be due to
potential activation of cultured cells during the course of
isolation from kidney and/or incubation in culture con-
ditions. Another inconsistency was that high glucose or
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Gas6 stimulation did not increase Akt or 4E-BP-1 ex-
pression in vitro, but in vivo, the expression of these two
molecules was increased in a diabetic condition. We think
that this might be due to a short exposure period. In vitro,
mesangial cells were exposed only for 36 hours, while in
vivo, 12 weeks.
Akt expression is known to be regulated by NF-jB
in vitro [37]. However, the regulation of p70 S6 kinase
and 4E-BP-1 expression is still unclear. Further study is
necessary to determine the involvement of NF-kB in Akt-
mediated signaling in vivo.
We previously reported that Gas6 can activate p44/42
MAP kinase in vitro [27], and that p44/42 MAP kinase is
phosphorylated in diabetic rat glomeruli after 12 weeks of
STZ injection, and this was inhibited by warfarin treat-
ment [12]. Although we have not determined the role
of p44/42 MAP kinase in this study, the role of p44/42
MAP kinase in diabetic nephropathy has been studied
by several investigators. For example, connective tissue
growth factor can induce extracellular matrix protein pro-
duction and cell migration via p44/42 MAP kinase and
Akt in mesangial cells in vitro [38]. Inhibition of the
diacylglycerol-protein kinase C-p44/42 MAP kinase path-
way improved albuminuria and excessive production of
extracellular matrix proteins in both type I and II diabetic
animal models [39–41]. Hence, it is still possible that the
MAP kinase pathway is important for other cellular re-
sponses to Gas6 in diabetic nephropathy.
We have shown that Gas6 was up-regulated in a high
glucose state in vivo and in vitro. Gas6 was originally
cloned from serum-starved fibroblasts [42], and its pro-
duction depends on the degree of growth arrest in NIH
3T3 cells. Meanwhile, p27 is one of the regulators of cell
cycle and induces G1 phase cell cycle arrest [5]. p27 is up-
regulated in diabetic glomeruli and the molecular mech-
anism of mesangial hypertrophy in diabetic renal disease
is, at least in part, explained by G1 phase cell cycle ar-
rest. In our study, warfarin treatment of diabetic rats re-
duced the expression of p27 in diabetic rat glomeruli.
Increased p27 expression in diabetic glomeruli might be
explained by the induction of Gas6 in mesangial cells
by high glucose state and that this might compose a vi-
cious cycle to arrest DNA synthesis, followed by hyper-
trophy in mesangial cells. Although the up-regulation
of Gas6 by high glucose stimulation is relatively weak
in vitro, this might be due to the weakness of stimula-
tion by high glucose. Stimulation of mesangial cells for
a longer period of time might result in more enhance-
ment of Gas6 in vivo, and further studies will be needed
to explore the mechanism of Gas6 expression in diabetic
state.
We previously suggested that warfarin therapy might
have potential as a therapeutic drug for diabetic
nephropathy at significantly lower concentrations than
the usual dose [12]. Warfarin therapy ameliorated hy-
perfiltration and urine albumin excretion in STZ-rats.
Warfarin also inhibits mesangial and glomerular hyper-
trophy in vivo and in vitro, suggesting that hypertrophy
and hyperfiltration might be an interactive mechanism
and presumed to be causally linked in the early phase of
diabetic nephropathy [12]. The present study reconfirms
warfarin’s possibility as an antihypertrophic therapeu-
tic drug, especially in the initial phase of diabetic renal
disease, by inhibiting the Akt/mTOR pathway through
blocking of Gas6.
In this study we used rapamycin, an immunosuppres-
sive agent, now available for organ transplantation in hu-
man. Our study suggests that rapamycin might be able to
inhibit mesangial hypertrophy in diabetic nephropathy.
Gooch et al reported that IGF-1 can also induce mesan-
gial hypertrophy via a calcineurin-dependent pathway,
which indicates that another immunosuppressive agent,
cyclosporine A, can prevent the mesangial hypertrophy
in diabetes [18]. There is another report from Utimura
et al that mycophenolate mofetil (MMF) ameliorated
glomerular hypertrophy and glomerulosclerosis in ex-
perimental diabetic nephropathy [43]. They suggest that
this effect of MMF can be mediated through its anti-
inflammatory effects. Although the direct effect of MMF
on mesangial cells is not shown, it is possible that MMF
can also affect mesangial hypertrophy. Thus, these im-
munosuppressive drugs might prevent the progression
of diabetic nephropathy by inhibiting mesangial hyper-
trophy in addition to their immunosuppressive and anti-
inflammatory effects.
CONCLUSION
We propose a new mechanism for mesangial hypertro-
phy in diabetic nephropathy from our study. It begins with
high glucose stimulation of mesangial cells, followed by
induction and activation of Gas6/Axl and the Akt/mTOR
pathway, which leads to mesangial and glomerular hy-
pertrophy. These data raise the intriguing possibility that
Akt/mTOR activation might be a common main pathway
in mesangial hypertrophy and, thus, play a crucial role in
the development of glomerular hypertrophy in the early
phase of diabetic nephropathy.
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